Cargando…
Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing...
Autores principales: | Buju, Roger T., Akilimali, Pierre Z., Kamangu, Erick N., Mesia, Gauthier K., Kayembe, Jean Marie N., Situakibanza, Hippolyte N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834045/ https://www.ncbi.nlm.nih.gov/pubmed/35162109 http://dx.doi.org/10.3390/ijerph19031085 |
Ejemplares similares
-
Incidence and Predictors of Loss to Follow Up among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
por: Buju, Roger T., et al.
Publicado: (2022) -
Determinants of Survival of HIV Patients Receiving Dolutegravir: A Prospective Cohort Study in Conflict-Affected Bunia, Democratic Republic of Congo
por: Buju, Roger T., et al.
Publicado: (2022) -
Epidemiological, clinical and biological profile of neuromeningeal cryptococcosis among people living with HIV in Kinshasa, Democratic Republic of Congo
por: Zono, Bive, et al.
Publicado: (2020) -
Determinants of Patients’ Adherence to Malaria Treatment in the Democratic Republic of the Congo
por: Ntamabyaliro, Nsengi Y., et al.
Publicado: (2022) -
Falciparum malaria molecular drug resistance in the Democratic Republic of Congo: a systematic review
por: Mvumbi, Dieudonné Makaba, et al.
Publicado: (2015)